Terms: = Lung cancer AND PPFIBP1, L2, 8496, ENSG00000110841, hSGT2, hSgt2p AND Prognosis
30 results:
1. sPD-L1 and sPD-L2 in plasma of patients with lung cancer and their clinical significance.
Han S; Zhang Y; Yuan J; Wu Y; Zhou Y; Zhou Y; Li X; Zhou S
Cytokine; 2024 Apr; 176():156532. PubMed ID: 38330638
[TBL] [Abstract] [Full Text] [Related]
2. Missing prognostic value of soluble PD-1, PD-L1 and PD-L2 in lung cancer patients undergoing chemotherapy - A CEPAC-TDM biomarker substudy.
Geiger K; Joerger M; Roessler M; Hettwer K; Ritter C; Simon K; Uhlig S; Holdenrieder S
Tumour Biol; 2024; 46(s1):S355-S367. PubMed ID: 38277316
[TBL] [Abstract] [Full Text] [Related]
3. A novel necroptosis signature for predicting survival in lung adenocarcinoma.
Zang K; Wang M; Zhu X; Yao B; Huang Y
BMC Med Genomics; 2023 Nov; 16(1):305. PubMed ID: 38017445
[TBL] [Abstract] [Full Text] [Related]
4. STARD12/14 are diagnostic and prognostic biomarkers of lung adenocarcinoma associated with epigenetic regulation, immune infiltration and ferroptosis.
Zhang WD; Hu DM; Shi ZE; Wang QX; Zhang MY; Liu JY; Ji XL; Qu YQ
Int J Med Sci; 2023; 20(11):1427-1447. PubMed ID: 37790851
[No Abstract] [Full Text] [Related]
5. PD-L2 overexpression on tumor-associated macrophages is one of the predictors for better prognosis in lung adenocarcinoma.
Matsubara E; Shinchi Y; Komohara Y; Yano H; Pan C; Fujiwara Y; Ikeda K; Suzuki M
Med Mol Morphol; 2023 Dec; 56(4):250-256. PubMed ID: 37402054
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic Value of EMT Gene Signature in Malignant Mesothelioma.
Wu L; Yoshihara K; Yun H; Karim S; Shokri N; Zaeimi F; Man HSJ; Zia A; Felley-Bosco E; de Perrot M
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901697
[TBL] [Abstract] [Full Text] [Related]
7. Construction and Preclinical Evaluation of a
Yao Y; Hou X; Liu S; Liu T; Ren Y; Ma X; Zhang Q; Wang P; Guo Q; Ma X; Yang Z; Zhu H; Li N
Mol Pharm; 2023 Feb; 20(2):1365-1374. PubMed ID: 36579764
[TBL] [Abstract] [Full Text] [Related]
8. Investigation of pd-l1 (cd274), pd-l2 (pdcd1lg2), and ctla-4 expressions in malignant pleural mesothelioma by immunohistochemistry and real-time polymerase chain reaction methods.
Sule Kutlar Dursun F; Alabalik U
Pol J Pathol; 2022; 73(2):111-119. PubMed ID: 36172747
[TBL] [Abstract] [Full Text] [Related]
9. Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma.
Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Shimokawa M; Suzuki K
Lung Cancer; 2022 Jun; 168():50-58. PubMed ID: 35489160
[TBL] [Abstract] [Full Text] [Related]
10. Lin28B-high breast cancer cells promote immune suppression in the lung pre-metastatic niche via exosomes and support cancer progression.
Qi M; Xia Y; Wu Y; Zhang Z; Wang X; Lu L; Dai C; Song Y; Xu K; Ji W; Zhan L
Nat Commun; 2022 Feb; 13(1):897. PubMed ID: 35173168
[TBL] [Abstract] [Full Text] [Related]
11. Arginase Pathway Markers of Immune-Microenvironment in Thymic Epithelial Tumors and Small Cell lung cancer.
Umemura S; Chen V; Chahine JJ; Kallakury B; Zhao X; Lee H; Avantaggiati ML; He Y; Wang C; Giaccone G
Clin Lung Cancer; 2022 Mar; 23(2):e140-e147. PubMed ID: 34393062
[TBL] [Abstract] [Full Text] [Related]
12. Cauda equina syndrome from intradural metastasis of a non-neural tumor: case report and review of literature.
Pagano A; Iaquinandi A; Fraioli MF; Bossone G; Carra N; Salvati M
Br J Neurosurg; 2023 Dec; 37(6):1487-1494. PubMed ID: 34330176
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic and clinicopathological value of PD-L2 in lung cancer: A meta-analysis.
Lin X; Lin K; Lin C; Liu T; Ba M; Tang Y; Wang J; Zhou L; Wang J; Xiao C
Int Immunopharmacol; 2021 Feb; 91():107280. PubMed ID: 33370681
[TBL] [Abstract] [Full Text] [Related]
14. Predicting postoperative non-small cell lung cancer prognosis via long short-term relational regularization.
Hu D; Li S; Huang Z; Wu N; Lu X
Artif Intell Med; 2020 Jul; 107():101921. PubMed ID: 32828458
[TBL] [Abstract] [Full Text] [Related]
15. Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report.
Nishino K; Kunimasa K; Kimura M; Inoue T; Tamiya M; Kuhara H; Kumagai T
BMC Pharmacol Toxicol; 2020 Apr; 21(1):26. PubMed ID: 32245391
[TBL] [Abstract] [Full Text] [Related]
16. Programmed Cell Death Ligand Expression Drives Immune Tolerogenesis across the Diverse Subtypes of Neuroendocrine Tumours.
Pinato DJ; Vallipuram A; Evans JS; Wong C; Zhang H; Brown M; Dina RE; Trivedi P; Akarca AU; Marafioti T; Mauri FA; Sharma R
Neuroendocrinology; 2021; 111(5):465-474. PubMed ID: 32097935
[TBL] [Abstract] [Full Text] [Related]
17. NGS-analysis to the rescue: dual checkpoint inhibition in metastatic osteosarcoma - a case report and review of the literature.
Nuytemans L; Sys G; Creytens D; Lapeire L
Acta Clin Belg; 2021 Apr; 76(2):162-167. PubMed ID: 31635553
[No Abstract] [Full Text] [Related]
18. A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal cancer.
Floudas CS; Brar G; Mabry-Hrones D; Duffy AG; Wood B; Levy E; Krishnasamy V; Fioravanti S; Bonilla CM; Walker M; Morelli MP; Kleiner DE; Steinberg SM; Figg WD; Greten TF; Xie C
Clin Colorectal Cancer; 2019 Dec; 18(4):e349-e360. PubMed ID: 31351862
[TBL] [Abstract] [Full Text] [Related]
19. [Treatment-related Skin Toxicity Caused by Programmed Death-1 Inhibitor Nivolumab:
A Case Report].
Gao L; Yu Y; Lu S
Zhongguo Fei Ai Za Zhi; 2019 Apr; 22(4):250-254. PubMed ID: 31014445
[TBL] [Abstract] [Full Text] [Related]
20. JQ1, a BET-bromodomain inhibitor, inhibits human cancer growth and suppresses PD-L1 expression.
Liu K; Zhou Z; Gao H; Yang F; Qian Y; Jin H; Guo Y; Liu Y; Li H; Zhang C; Guo J; Wan Y; Chen R
Cell Biol Int; 2019 Jun; 43(6):642-650. PubMed ID: 30958600
[TBL] [Abstract] [Full Text] [Related]
[Next]
